Published in PLoS One on May 02, 2014
Argonaute2 is the catalytic engine of mammalian RNAi. Science (2004) 22.86
Crystal structure of Argonaute and its implications for RISC slicer activity. Science (2004) 12.48
Structural basis for overhang-specific small interfering RNA recognition by the PAZ domain. Nature (2004) 7.63
The crystal structure of the Argonaute2 PAZ domain reveals an RNA binding motif in RNAi effector complexes. Nat Struct Biol (2003) 6.90
A three-dimensional view of the molecular machinery of RNA interference. Nature (2009) 6.31
Structure and conserved RNA binding of the PAZ domain. Nature (2003) 5.28
Structure and nucleic-acid binding of the Drosophila Argonaute 2 PAZ domain. Nature (2003) 4.92
Nucleic acid 3'-end recognition by the Argonaute2 PAZ domain. Nat Struct Mol Biol (2004) 4.38
Identification of eight members of the Argonaute family in the human genome. Genomics (2003) 3.55
A comprehensive survey of 3' animal miRNA modification events and a possible role for 3' adenylation in modulating miRNA targeting effectiveness. Genome Res (2010) 2.87
Exact analysis of competition ligand binding by displacement isothermal titration calorimetry. Anal Biochem (2000) 2.50
Structure of yeast Argonaute with guide RNA. Nature (2012) 2.38
A review of antisense therapeutic interventions for molecular biological targets in asthma. Biologics (2007) 1.43
Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection. Mol Ther (2013) 1.42
Structural basis for piRNA 2'-O-methylated 3'-end recognition by Piwi PAZ (Piwi/Argonaute/Zwille) domains. Proc Natl Acad Sci U S A (2010) 1.40
Recognition of 2'-O-methylated 3'-end of piRNA by the PAZ domain of a Piwi protein. Structure (2011) 1.37
Argonaute and RNA--getting into the groove. Curr Opin Struct Biol (2006) 1.35
Increased siRNA duplex stability correlates with reduced off-target and elevated on-target effects. RNA (2011) 1.26
RNAi in clinical studies. Curr Med Chem (2013) 1.13
Argonaute identity defines the length of mature mammalian microRNAs. Nucleic Acids Res (2012) 1.00
Slicing-independent RISC activation requires the argonaute PAZ domain. Curr Biol (2012) 0.96
RNA interference: historical overview and significance. Methods Mol Biol (2004) 0.95
RNA interference: antiviral weapon and beyond. World J Gastroenterol (2003) 0.95
RNA interference--a silent but an efficient therapeutic tool. Appl Biochem Biotechnol (2013) 0.89
miRNA, siRNA, piRNA and argonautes: news in small matters. RNA Biol (2010) 0.88
Modified siRNAs for the study of the PAZ domain. Chem Commun (Camb) (2010) 0.87
Substrate specificity and nucleotides binding properties of NM23H2/nucleoside diphosphate kinase homolog from Plasmodium falciparum. J Bioenerg Biomembr (2010) 0.86
Bioinformatics, enzymologic properties, and comprehensive tracking of Plasmodium falciparum nucleoside diphosphate kinase. Biol Pharm Bull (2009) 0.86
Small interfering RNAs targeting the rabies virus nucleoprotein gene. Virus Res (2012) 0.86
Binding dynamics and energetic insight into the molecular forces driving nucleotide binding by guanylate kinase. J Mol Recognit (2010) 0.85
Small interfering RNA (siRNA)-mediated silencing of the M2 subunit of ribonucleotide reductase: a novel therapeutic strategy in ovarian cancer. Int J Gynecol Cancer (2013) 0.85
Synthesis of nuclease-resistant siRNAs possessing universal overhangs. Bioorg Med Chem (2009) 0.84
RNA interference-based gene therapy for successful treatment of rheumatoid arthritis. Expert Opin Biol Ther (2009) 0.84
Nucleotide bias of DCL and AGO in plant anti-virus gene silencing. Protein Cell (2010) 0.84
RNAi as an antiviral therapy. Expert Opin Biol Ther (2005) 0.82
Computational analysis of siRNA recognition by the Ago2 PAZ domain and identification of the determinants of RNA-induced gene silencing. PLoS One (2013) 0.80
MicroRNA and brain tumors: a cause and a cure? DNA Cell Biol (2007) 0.80
Structural insights into piRNA recognition by the human PIWI-like 1 PAZ domain. Proteins (2011) 0.80
In silico molecular docking analysis of the human Argonaute 2 PAZ domain reveals insights into RNA interference. J Comput Aided Mol Des (2013) 0.79
Synthesis and biological properties of chemically modified siRNAs bearing 1-deoxy-D-ribofuranose in their 3'-overhang region. Bioorg Med Chem Lett (2012) 0.78
Synthesis of nuclease-resistant siRNAs possessing benzene-phosphate backbones in their 3'-overhang regions. Bioorg Med Chem Lett (2008) 0.78
Anti-HBV efficacy of combined siRNAs targeting viral gene and heat shock cognate 70. Virol J (2012) 0.78
Expanding the repertoire of RNA interference screens for developing new anticancer drug targets. Expert Opin Ther Targets (2007) 0.78
The substrate binding preferences of Plasmodium thymidylate kinase. Biol Pharm Bull (2011) 0.76
Structural and binding study of modified siRNAs with the Argonaute 2 PAZ domain by NMR spectroscopy. Chemistry (2011) 0.76
Silencing of c-kit with small interference RNA attenuates inflammation in a murine model of allergic asthma. Int J Mol Med (2012) 0.76
Synthesis and silencing properties of siRNAs possessing lipophilic groups at their 3'-termini. Bioorg Med Chem (2008) 0.76